Can a new pill slow Alzheimer's? major trial launches

NCT ID NCT07191028

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether MLC901 (NeuroAiD™II) can improve thinking and memory in people with mild to moderate Alzheimer's disease. About 350 adults aged 50 and older will receive either the study drug or a placebo for several months. Researchers will measure changes in cognitive tests and blood markers to see if the treatment is safe and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National University Hospital Singapore

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.